tirzepatide use in pregnancy Pre‐Pregnancy GLP‐1 Receptor Agonist or and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry‐Over Versus Post‐Discontinuation Metabolic Rebound a Multinational Federated Cohort Planning a pregnancy on a

No exceptions for this formulation

Hear from our patients patients Frequently asked questions questions In clinical trials, patients lost an average of 20% of their body weight when Zepbound was paired with lifestyle changes

Pricing changes frequently, so confirm at your visit

Understanding the expected timeline and factors influencing recovery helps set realistic patient expectations and guides ongoing management decisions

Use caution with insulin or sulfonylureas (hypoglycemia risk) and with a history of gallbladder disease or diabetic retinopathy

As a result, they may require higher doses or more frequent administration to achieve the desired results